Novo Nordisk Cuts Ozempic Prices for Uninsured Canadians
Event summary
- Novo Nordisk Canada will reduce Ozempic costs for uninsured patients starting May 29, 2026, aligning prices with generic alternatives.
- Over 1 million Canadians currently use semaglutide (Ozempic's active ingredient).
- Savings cards will be available at pharmacies nationwide except Quebec, with automatic application at Novo Nordisk Care® Rx and select partners.
- Iain Graham, General Manager of Novo Nordisk Canada, emphasizes maintaining patient access to the brand-name medication.
The big picture
Novo Nordisk's move to lower Ozempic prices for uninsured Canadians reflects broader industry trends in pharmaceutical pricing strategies aimed at maintaining market dominance amid generic competition. The initiative underscores the company's focus on patient retention and access, particularly in a market where chronic disease management is a growing priority. With over 1 million Canadians using semaglutide, the pricing adjustment could set a precedent for how brand-name drugs compete with generics in Canada.
What we're watching
- Market Share Defense
- How Novo Nordisk's price adjustment will affect competition with generic semaglutide alternatives.
- Regulatory Scrutiny
- Whether Health Canada will review the pricing strategy for compliance with healthcare policies.
- Patient Retention
- The pace at which uninsured patients switch to or remain on Ozempic following the cost reduction.
Related topics